

Status: Currently Official on 13-Feb-2025
Official Date: Official as of 01-May-2022
Document Type: USP Monographs
DocId: GUID-3B4970C2-D8E8-410C-8DA5-B138B73D6962_5_en-US
DOI: https://doi.org/10.31003/USPNF_M2603_05_01
DOI Ref: y0kcr

© 2025 USPC
Do not distribute

Amifostine for Injection

DEFINITION

Amifostine for Injection is a sterile, crystalline substance suitable for parenteral use. It contains NLT 90.0% and NMT 110.0% of the labeled amount of amifostine ($C_5H_{15}N_2O_3PS$).

IDENTIFICATION

- **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197K](#)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Buffer: 0.94 g/L of sodium 1-hexanesulfonate. Adjust with phosphoric acid to a pH of 3.0.

Mobile phase: Methanol and *Buffer* (7:18)

Standard solution: 3 mg/mL of [USP Amifostine RS](#) in water. [NOTE—Inject immediately after preparation, or refrigerate until use.]

Sample solution: 3 mg/mL of amifostine from Amifostine for Injection, in water. [NOTE—Inject immediately after preparation, or refrigerate until use.]

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm × 25-cm; 5-μm packing L7

Autosampler temperature: 4°

Flow rate: 1.0 mL/min

Injection size: 10 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Column efficiency: NLT 1000 theoretical plates

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of $C_5H_{15}N_2O_3PS$ in the portion of Amifostine for Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak responses from the *Sample solution*

r_S = peak responses from the *Standard solution*

C_S = concentration of [USP Amifostine RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of amifostine in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements

IMPURITIES

ORGANIC IMPURITIES

• PROCEDURE 1

Mobile phase and **Chromatographic system:** Proceed as directed in the Assay.

Standard solution 1: 70 μg/mL of [USP Amifostine Thiol RS](#) in water

Standard solution 2: 15 µg/mL of sodium thiophosphate and 13 µg/mL of *N,N*-dimethylformamide in water. [NOTE—The retention times of sodium thiophosphate and *N,N*-dimethylformamide are about 2 min and about 3.6 min, respectively.]

Sample solution: 2.4 mg/mL of amifostine from Amifostine for Injection in water. [NOTE—Inject immediately after preparation.]

System suitability

Samples: *Standard solution 1* and *Standard solution 2*

Suitability requirements

Relative standard deviation: NMT 10.0%, *Standard solution 1*; NMT 4.0%, *Standard solution 2*

Analysis

Samples: *Standard solution 1*, *Standard solution 2*, and *Sample solution*

Calculate the percentage of amifostine thiol in the portion of sample taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of amifostine thiol from the *Sample solution*

r_S = peak response of amifostine thiol from *Standard solution 1*

C_S = concentration of [USP Amifostine Thiol RS](#) in *Standard solution 1* (mg/mL)

C_U = concentration of amifostine in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of amifostine thiol, 134.24

M_{r2} = molecular weight of amifostine thiol dihydrochloride, 207.17

Calculate the percentage of sodium thiophosphate or *N,N*-dimethylformamide in the portion of sample taken, if present:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of sodium thiophosphate or *N,N*-dimethylformamide from the *Sample solution*

r_S = peak response of sodium thiophosphate or *N,N*-dimethylformamide from *Standard solution 2*

C_S = concentration of sodium thiophosphate or *N,N*-dimethylformamide in *Standard solution 2* (mg/mL)

C_U = concentration of amifostine in the *Sample solution* (mg/mL)

Calculate the percentage of any other individual, unspecified impurity in the portion of sample taken:

$$\text{Result} = (r_U/r_T) \times 100$$

r_U = peak response of each individual impurity in the *Sample solution*

r_T = total of all peak responses in the *Sample solution*

Acceptance criteria: NMT 0.1% of sodium thiophosphate; NMT 0.088% of *N,N*-dimethylformamide; NMT 0.1% of any other individual unspecified impurity

• PROCEDURE 2

Buffer: 0.4 g/L of sodium 1-octanesulfonate. Adjust with trifluoroacetic acid to a pH of 2.5 ± 0.1 .

Mobile phase: Acetonitrile and *Buffer* (1:3)

Standard solution: 46 µg/mL of [USP Amifostine Disulfide RS](#) in water

Sample solution: Dilute a quantity of Amifostine for Injection in water to prepare a solution equivalent to 10 mg/mL. [NOTE—Inject immediately after preparation.]

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 247 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Autosampler temperature: 4°

Flow rate: 1.0 mL/min

Injection size: 10 µL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.5

Relative standard deviation: NMT 4.0%